Zhang Dan, Ge Lei, Li Jing, Li Xi, Feng Fang, Chen Yi-ping, Chen Zheng-ming, Martin Landray, Jane Armitage, Chen Fang, Jiang Li-xin
China Oxford Centre for International Health Research Cardiovascular Institute, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2011 May;39(5):397-401.
To investigate the current statin use among high-risk patients with atherosclerotic cardiovascular diseases in Chinese large hospitals.
Clinical history and current medication were recorded in 11 783 patients with a history of atherosclerotic cardiovascular disease (CVD) from 39 highest-ranking hospitals in 10 Chinese cities.
Indication for statin use was given for all screened patients and statin was not prescribed in up to 59.6% (7022) patients. For patients with statin use, medication time was shorter than their atherosclerotic CVD history in 1120 (23.5%) patients. The proportion of statin use among patients with ischemic stroke was 19.6%, among patients with coronary heart disease without ischemic stroke was 59.2%.
Statin is underused in secondary prevention among patients with atherosclerotic CVD in China. There is a large gap between guideline recommended statin use and in practice. Thus, it remains a major challenge for healthcare professionals and policy makers to resolve this problem rapidly.
调查中国大型医院中高危动脉粥样硬化性心血管疾病患者目前他汀类药物的使用情况。
记录来自中国10个城市39家顶级医院的11783例有动脉粥样硬化性心血管疾病（CVD）病史患者的临床病史和当前用药情况。
所有筛查患者均有使用他汀类药物的指征，但高达59.6%（7022例）的患者未开具他汀类药物。在使用他汀类药物的患者中，1120例（23.5%）患者的用药时间短于其动脉粥样硬化性CVD病史。缺血性卒中患者中他汀类药物的使用率为19.6%，无缺血性卒中的冠心病患者中为59.2%。
在中国，他汀类药物在动脉粥样硬化性CVD患者的二级预防中使用不足。指南推荐的他汀类药物使用与实际应用之间存在很大差距。因此，迅速解决这一问题对医疗专业人员和政策制定者来说仍然是一项重大挑战。
